{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:08:58Z","timestamp":1793830138842,"version":"4.6.1"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Brazilian Society of Rheumatology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Spondyloarthritis (SpA) is a group of chronic inflammatory systemic diseases characterized by axial and\/or peripheral joints inflammation, as well as extra-articular manifestations. Over some decades, nonsteroidal anti-inflammatory drugs (NSAIDs) have been the basis for the pharmacological treatment of patients with axial spondyloarthritis (axSpA). However, the emergence of the immunobiologic agents brought up the discussion about the role of NSAIDs in the management of these patients. The objective of this guideline is to provide recommendations for the use of NSAIDs for the treatment of axSpA. A panel of experts from the Brazilian Society of Rheumatology conducted a systematic review and meta-analysis of randomized clinical trials for 15 predefined questions. The Grading of Recommendations, Assessment, Development and Evaluation methodology to assess the quality of evidence and formulate recommendations were used, and at least 70% agreement of the voting panel was needed. Fourteen recommendations for the use of NSAIDs in the treatment of patients with axSpA were elaborated. The purpose of these recommendations is to support clinicians\u2019 decision making, without taking out his\/her autonomy when prescribing for an individual patient.<\/jats:p>","DOI":"10.1186\/s42358-020-00160-6","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T09:02:51Z","timestamp":1611046971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis"],"prefix":"10.1186","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6220-8585","authenticated-orcid":false,"given":"Ricardo","family":"da Cruz Lage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Diniz Lopes","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thauana Luiza","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Gomes","family":"Resende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Lubianca","family":"Kohem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Gon\u00e7alves","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f4nio Carlos","family":"Ximenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lio Roberto","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Washington Alves","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"de Souza Meirelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro Waldemar","family":"Keiserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Chiereghin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano Barbosa","family":"Campanholo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Marun","family":"Lyrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udia Goldenstein","family":"Schainberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenise Brandao","family":"Pieruccetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel Alexandre","family":"Yazbek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope Esther","family":"Palominos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela Silva Guimar\u00e3es","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Luppino","family":"Assad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubens","family":"Bonfiglioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f4nia Maria Alvarenga Anti Loduca","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sueli","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valder\u00edlio Feij\u00f3","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleandro Pires","family":"Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanderley Marques","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Percival Degrava","family":"Sampaio-Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"de Medeiros Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"issue":"6","key":"160_CR1","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1136\/ard.2009.108217","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Landewe R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009;68(6):770\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"160_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"160_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"160_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361\u20138.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"160_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/art.37803","volume":"65","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D. Review: Nonradiographic axial spondyloarthritis: new definition of an old disease? Arthritis Rheum. 2013;65(3):543\u201351.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"160_CR6","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"160_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s42358-020-0116-2","volume":"60","author":"GG Resende","year":"2020","unstructured":"Resende GG, Meirelles ES, Marques CDL, Chiereghin A, Lyrio AM, Ximenes AC, et al. The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis - 2019. Adv Rheumatol. 2020;60(1):19.","journal-title":"Adv Rheumatol"},{"key":"160_CR8","doi-asserted-by":"crossref","unstructured":"FPB K, der Burg LRA v, Ramiro S, RBM L, Buchbinder R, Falzon L, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015;17(7):CD010952-CD.","DOI":"10.1002\/14651858.CD010952.pub2"},{"issue":"1","key":"160_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/rheumatology\/kew367","volume":"56","author":"X Baraliakos","year":"2017","unstructured":"Baraliakos X, Kiltz U, Peters S, Appel H, Dybowski F, Igelmann M, et al. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. Rheumatology (Oxford). 2017;56(1):95\u2013102.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"160_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/injr.injr_64_17","volume":"13","author":"M Bhuvanesh","year":"2018","unstructured":"Bhuvanesh M, Balaji C, Saranya C, Ramesh R, Tamilselvam T, Rajeswari S. Serum levels of tumor necrosis factor-alpha and vascular endothelial growth factor as markers of disease activity in patients with axial spondyloarthritis. Indian J Rheumatol. 2018;13(1):9\u201313.","journal-title":"Indian J Rheumatol"},{"issue":"1","key":"160_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1136\/annrheumdis-2014-206147","volume":"75","author":"I Essers","year":"2016","unstructured":"Essers I, Stolwijk C, Boonen A, De Bruin ML, Bazelier MT, de Vries F, et al. Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Ann Rheum Dis. 2016;75(1):203\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"160_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.17116\/terarkh201789678-83","volume":"89","author":"IZ Gaydukova","year":"2017","unstructured":"Gaydukova IZ, Gamayunova Cyrillic A cKA, Dorogoykina KD, Rebrov AP. Efficiency of different celecoxib regimens in patients with active axial spondyloarthritis: Results of the 4-week pilot open-label comparative single-center study \u2018AIM\u2019. Ter Arkh. 2017;89(6):78\u201383.","journal-title":"Ter Arkh"},{"issue":"3","key":"160_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.17116\/terarkh201587377-82","volume":"87","author":"IZ Gaydukova","year":"2015","unstructured":"Gaydukova IZ, Rebrov AP. Efficiency and safety of different etoricoxib regimens in patients with axial spondyloarthritis, including ankylosing spondylitis. Ter Arkh. 2015;87(3):77\u201382.","journal-title":"Ter Arkh"},{"issue":"1","key":"160_CR14","first-page":"94","volume":"34","author":"J Gratacos","year":"2016","unstructured":"Gratacos J, Moreno Martinez-Losa M, Font P, Montilla C, Fernandez-Espartero C, Linares LF, et al. Etoricoxib in ankylosing spondylitis: is there a role for active patients refractory to traditional NSAIDs? Clin Exp Rheumatol. 2016;34(1):94\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"160_CR15","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jbspin.2014.01.003","volume":"81","author":"D Guellec","year":"2014","unstructured":"Guellec D, Nocturne G, Tatar Z, Pham T, Sellam J, Cantagrel A, et al. Should non-steroidal anti-inflammatory drugs be used continuously in ankylosing spondylitis? Joint Bone Spine. 2014;81(4):308\u201312.","journal-title":"Joint Bone Spine"},{"issue":"Suppl 2","key":"160_CR16","first-page":"1144 LP","volume":"74","author":"A Karateev","year":"2015","unstructured":"Karateev A, Chernikhova E, Erdes S. AB0735 Upper Gastrointestinal Tract Pathology in Patients with Ankylosing Spondylitis. Ann Rheum Dis. 2015;74(Suppl 2):1144 LP.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"160_CR17","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/acr.22555","volume":"67","author":"LE Kristensen","year":"2015","unstructured":"Kristensen LE, Jakobsen AK, Askling J, Nilsson F, Jacobsson LTH. Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study. Arthritis Care Res. 2015;67(8):1137\u201349.","journal-title":"Arthritis Care Res"},{"issue":"5","key":"160_CR18","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/acr.22980","volume":"69","author":"F Maas","year":"2017","unstructured":"Maas F, Spoorenberg A, van der Slik BPG, van der Veer E, Brouwer E, Bootsma H, et al. Clinical Risk Factors for the Presence and Development of Vertebral Fractures in Patients With Ankylosing Spondylitis. Arthritis Care Res. 2017;69(5):694\u2013702.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"160_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jbspin.2016.01.013","volume":"84","author":"A Molto","year":"2017","unstructured":"Molto A, Granger B, Wendling D, Dougados M, Gossec L. Use of nonsteroidal anti-inflammatory drugs in early axial spondyloarthritis in daily practice: Data from the DESIR cohort. Joint Bone Spine. 2017;84(1):79\u201382.","journal-title":"Joint Bone Spine"},{"issue":"1","key":"160_CR20","doi-asserted-by":"publisher","first-page":"e000397-e","DOI":"10.1136\/rmdopen-2016-000397","volume":"3","author":"A Regel","year":"2017","unstructured":"Regel A, Sepriano A, Baraliakos X, van der Heijde D, Braun J, Landewe R, et al. Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017;3(1):e000397-e.","journal-title":"RMD Open"},{"issue":"3","key":"160_CR21","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/1756-185X.12986","volume":"20","author":"H-W Tam","year":"2017","unstructured":"Tam H-W, Yeo K-J, Leong P-Y, Chen C-H, Li Y-C, Ma C-M, et al. Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study. Int J Rheum Dis. 2017;20(3):363\u201370.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"160_CR22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10067-017-3666-x","volume":"37","author":"M Tang","year":"2018","unstructured":"Tang M, Xue L, Shen Y, Bo L, Yang R, Wen J, et al. Efficacy of long-term nonsteroidal antiinflammatory drug treatment on magnetic resonance imaging-determined bone marrow oedema in early, active axial spondyloarthritis patients. Clin Rheumatol. 2018;37(1):245\u201350.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"160_CR23","doi-asserted-by":"publisher","first-page":"e0126347-e","DOI":"10.1371\/journal.pone.0126347","volume":"10","author":"W-C Tsai","year":"2015","unstructured":"Tsai W-C, Ou T-T, Yen J-H, Wu C-C, Tung Y-C. Long-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study. PLoS One. 2015;10(5):e0126347-e.","journal-title":"PLoS One"},{"issue":"3","key":"160_CR24","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/art.39474","volume":"68","author":"G Varkas","year":"2016","unstructured":"Varkas G, Jans L, Cypers H, Van Praet L, Carron P, Elewaut D, et al. Brief Report: Six-Week Treatment of Axial Spondyloarthritis Patients With an Optimal Dose of Nonsteroidal Antiinflammatory Drugs: Early Response to Treatment in Signal Intensity on Magnetic Resonance Imaging of the Sacroiliac Joints. Arthritis Rheumatol (Hoboken, NJ). 2016;68(3):672\u20138.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"6","key":"160_CR25","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1136\/annrheumdis-2015-207677","volume":"75","author":"R Wang","year":"2016","unstructured":"Wang R, Dasgupta A, Ward MM. Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis. 2016;75(6):1152\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"36","key":"160_CR26","doi-asserted-by":"publisher","first-page":"e4792-e","DOI":"10.1097\/MD.0000000000004792","volume":"95","author":"L-C Wu","year":"2016","unstructured":"Wu L-C, Leong P-Y, Yeo K-J, Li T-Y, Wang Y-H, Chiou J-Y, et al. Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. Medicine. 2016;95(36):e4792-e.","journal-title":"Medicine"},{"issue":"6","key":"160_CR27","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3899\/jrheum.170133","volume":"45","author":"M Couderc","year":"2018","unstructured":"Couderc M, Pereira B, Molto A, Tiple A, Soubrier M, Dougados M. The Prevalence of Renal Impairment in Patients with Spondyloarthritis: Results from the International ASAS-COMOSPA Study. J Rheumatol. 2018;45(6):795\u2013801.","journal-title":"J Rheumatol"},{"issue":"23","key":"160_CR28","first-page":"1867","volume":"103","author":"A Dregan","year":"2017","unstructured":"Dregan A, Chowienczyk P, Molokhia M. Cardiovascular and type 2 diabetes morbidity and all-cause mortality among diverse chronic inflammatory disorders. Heart (British Cardiac Society). 2017;103(23):1867\u201373.","journal-title":"Heart (British Cardiac Society)"},{"key":"160_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.intimp.2017.11.003","volume":"54","author":"MJ Fattahi","year":"2018","unstructured":"Fattahi MJ, Jamshidi AR, Mahmoudi M, Vojdanian M, Yekaninejad MS, Jafarnezhad-Ansariha F, et al. Evaluation of the efficacy and safety of beta-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I\/II clinical trial. Int Immunopharmacol. 2018;54:112\u20137.","journal-title":"Int Immunopharmacol"},{"issue":"Suppl 2","key":"160_CR30","first-page":"344 LP","volume":"76","author":"G Gao","year":"2017","unstructured":"Gao G, Lu L, Li Z, Li Y. THU0367 The influences of non-steroidal anti-inflammatory drugs on serum VEGF and BMP-2 levels in patients with axial spondyloarthritis. Ann Rheum Dis. 2017;76(Suppl 2):344 LP.","journal-title":"Ann Rheum Dis"},{"key":"160_CR31","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.12659\/MSM.901727","volume":"23","author":"G-M Gao","year":"2017","unstructured":"Gao G-M, Li Y-M, Zheng X-L, Jiang D-B, Zhang L-L, Xu P-H, et al. The Efficacy of Imrecoxib and Celecoxib in Axial Spondyloarthritis and Their Influence on Serum Dickopff-Related Protein 1 (DKK-1) Levels. Med Sci Monit. 2017;23:2985\u201392.","journal-title":"Med Sci Monit"},{"issue":"2","key":"160_CR32","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10787-017-0386-4","volume":"26","author":"F Jafarnezhad-Ansariha","year":"2018","unstructured":"Jafarnezhad-Ansariha F, Yekaninejad MS, Jamshidi A-R, Mansouri R, Vojdanian M, Mahmoudi M, et al. The effects of beta-D-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte\/macrophage, J774 cell line. Inflammopharmacology. 2018;26(2):375\u201384.","journal-title":"Inflammopharmacology."},{"key":"160_CR33","volume-title":"Profiling ankylosing spondylitis patients likely to respond to NSAID treatment","author":"M Bedaiwi","year":"2014","unstructured":"Bedaiwi M, Thavaneswaran A, Haroon N, Anton A, Inman R. Profiling ankylosing spondylitis patients likely to respond to NSAID treatment; 2014."},{"issue":"Suppl 2","key":"160_CR34","doi-asserted-by":"publisher","first-page":"1150.1","DOI":"10.1136\/annrheumdis-2015-eular.5240","volume":"74","author":"O Zengin","year":"2015","unstructured":"Zengin O, K\u0131sac\u0131k B, Kimyon G, Uyar N, Onat AM. AB0751 Treatment Response in Spondylitis Without Sacroiliitis to Nonsteroidal Antiinflammatory Drugs is More Difficult than Axial Spondyloarthritis. Ann Rheum Dis. 2015;74(Suppl 2):1150.1.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"160_CR35","first-page":"1037 LP","volume":"73","author":"MD S\u00e1nchez","year":"2014","unstructured":"S\u00e1nchez MD, Montilla-Morales CA, G\u03ccmez-Castro S, Hidalgo-Calleja C, Carranco-Medina T, Calero-Paniagua I, et al. AB0705 Nonsteroidal Antiinflammatory Drugs and Bone Mineral Density and Fractures in Patients with Ankylosing Spondylitis. Ann Rheum Dis. 2014;73(Suppl 2):1037 LP.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"160_CR36","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1159\/000455167","volume":"135","author":"A Shukla","year":"2017","unstructured":"Shukla A, Rai MK, Prasad N, Agarwal V. Short-term non-steroid anti-inflammatory drug use in spondyloarthritis patients induces subclinical acute kidney injury: biomarkers study. Nephron. 2017;135(4):277\u201386.","journal-title":"Nephron."},{"issue":"6","key":"160_CR37","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/acr.22753","volume":"68","author":"MK Bedaiwi","year":"2016","unstructured":"Bedaiwi MK, Sari I, Wallis D, O'Shea FD, Salonen D, Haroon N, et al. Clinical efficacy of celecoxib compared to acetaminophen in chronic nonspecific low back pain: results of a randomized controlled trial. Arthritis Care Res. 2016;68(6):845\u201352.","journal-title":"Arthritis Care Res"},{"key":"160_CR38","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.curtheres.2014.08.002","volume":"76","author":"F Huang","year":"2014","unstructured":"Huang F, Gu J, Liu Y, Zhu P, Zheng Y, Fu J, et al. Efficacy and safety of celecoxib in chinese patients with ankylosing spondylitis: a 6-week randomized, double-blinded study with 6-week open-label extension treatment. Curr Ther Res Clin Exp. 2014;76:126\u201333.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"6","key":"160_CR39","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72(6):815\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"160_CR40","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/0300060516628704","volume":"44","author":"C Walker","year":"2016","unstructured":"Walker C, Essex MN, Li C, Park PW. Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients. J Int Med Res. 2016;44(3):483\u201395.","journal-title":"J Int Med Res"},{"issue":"1","key":"160_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-016-1275-5","volume":"17","author":"E Balazcs","year":"2016","unstructured":"Balazcs E, Sieper J, Bickham K, Mehta A, Frontera N, Stryszak P, et al. A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis. BMC Musculoskelet Disord. 2016;17(1):426.","journal-title":"BMC Musculoskelet Disord"},{"issue":"4","key":"160_CR42","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383\u201394.","journal-title":"J Clin Epidemiol"},{"issue":"7652","key":"160_CR43","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Going from evidence to recommendations. Bmj. 2008;336(7652):1049\u201351.","journal-title":"Bmj."},{"issue":"9","key":"160_CR44","first-page":"1805","volume":"33","author":"A Barkhuizen","year":"2006","unstructured":"Barkhuizen A, Steinfeld S, Robbins J, West C, Coombs J, Zwillich S. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol. 2006;33(9):1805\u201312.","journal-title":"J Rheumatol"},{"issue":"1","key":"160_CR45","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K","volume":"44","author":"M Dougados","year":"2001","unstructured":"Dougados M, Behier JM, Jolchine I, Calin A, van der Heijde D, Olivieri I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum. 2001;44(1):180\u20135.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"160_CR46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/rheumatology\/38.3.235","volume":"38","author":"M Dougados","year":"1999","unstructured":"Dougados M, Gueguen A, Nakache JP, Velicitat P, Veys EM, Zeidler H, et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford). 1999;38(3):235\u201344.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"160_CR47","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3109\/03009749409103723","volume":"23","author":"M Dougados","year":"1994","unstructured":"Dougados M, Nguyen M, Caporal R, Legeais J, Bouxin-Sauzet A, Pellegri-Guegnault B, et al. Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study. Scand J Rheumatol. 1994;23(5):243\u20138.","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"160_CR48","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/art.20985","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Baraf HSB, Ramos-Remus C, Calin A, Weaver AL, Schiff M, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum. 2005;52(4):1205\u201315.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"160_CR49","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/ard.2007.075309","volume":"67","author":"J Sieper","year":"2008","unstructured":"Sieper J, Klopsch T, Richter M, Kapelle A, Rudwaleit M, Schwank S, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis. 2008;67(3):323\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"160_CR50","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1136\/ard.2004.029611","volume":"64","author":"L Gossec","year":"2005","unstructured":"Gossec L, van der Heijde D, Melian A, Krupa DA, James MK, Cavanaugh PF, et al. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis. 2005;64(11):1563\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"160_CR51","first-page":"1194","volume":"23","author":"LF Villa Alcazar","year":"1996","unstructured":"Villa Alcazar LF, de Buergo M, Rico Lenza H, Montull Fruitos E. Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis: a 3 month multicenter comparative trial. Spanish Study Group on Aceclofenac in Ankylosing Spondylitis. J Rheumatol. 1996;23(7):1194\u20139.","journal-title":"J Rheumatol"},{"issue":"4A","key":"160_CR52","first-page":"660","volume":"33","author":"W Ebner","year":"1983","unstructured":"Ebner W, Poal Ballarin JM, Boussina I. Meclofenamate sodium in the treatment of ankylosing spondylitis. Report of a European double-blind controlled multicenter study. Arzneimittel-Forschung. 1983;33(4A):660\u20133.","journal-title":"Arzneimittel-Forschung."},{"issue":"1","key":"160_CR53","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1185\/03007997709108987","volume":"5","author":"A Good","year":"1977","unstructured":"Good A, Mena H. Treatment of ankylosing spondylitis with flurbiprofen and indomethacin. Curr Med Res Opin. 1977;5(1):117\u201321.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"160_CR54","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s10067-005-0132-y","volume":"25","author":"J Zochling","year":"2006","unstructured":"Zochling J, Bohl-Buhler MH, Baraliakos X, Feldtkeller E, Braun J. Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis--a population-based survey. Clin Rheumatol. 2006;25(6):794\u2013800.","journal-title":"Clin Rheumatol"},{"key":"160_CR55","doi-asserted-by":"crossref","unstructured":"Carbo MJG, Spoorenberg A, Maas F, Brouwer E, Bos R, Bootsma H, et al. Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-alpha inhibitors. PLoS One. 2018;13(4):e0196.","DOI":"10.1371\/journal.pone.0196281"},{"issue":"4","key":"160_CR56","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/ard.2005.041129","volume":"65","author":"J Zochling","year":"2006","unstructured":"Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS\/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis. 2006;65(4):423\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"160_CR57","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheum. 2016;68(5):1060\u201371.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"160_CR58","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499\u2013510.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"160_CR59","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2014;73(1):101\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"160_CR60","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/annrheumdis-2013-203460","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, et al. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis. 2014;73(1):108\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"160_CR61","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/art.24408","volume":"60","author":"N Barkham","year":"2009","unstructured":"Barkham N, Keen HI, Coates LC, O'Connor P, Hensor E, Fraser AD, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum. 2009;60(4):946\u201354.","journal-title":"Arthritis Rheum"},{"key":"160_CR62","first-page":"1285","volume":"63","author":"Z Ash","year":"2011","unstructured":"Ash Z, Barkham N, McGonagle D, Hensor E, Emery P, Marzo-Ortega H. Induction approach to early axial spondyloarthritis: still looking for the window of opportunity. Arthritis Rheum. 2011;63:1285.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"160_CR63","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3899\/jrheum.141278","volume":"42","author":"X Baraliakos","year":"2015","unstructured":"Baraliakos X, Koenig AS, Jones H, Szumski A, Collier D, Bananis E. Predictors of clinical remission under anti-tumor necrosis factor treatment in patients with ankylosing spondylitis: pooled analysis from large randomized clinical trials. J Rheumatol. 2015;42(8):1418\u201326.","journal-title":"J Rheumatol"},{"issue":"3","key":"160_CR64","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/ar4561","volume":"16","author":"PC Robinson","year":"2014","unstructured":"Robinson PC, Brown MA. The window of opportunity: a relevant concept for axial spondyloarthritis. Arthritis Res Ther. 2014;16(3):109.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"160_CR65","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/ard.2003.016386","volume":"63","author":"M Rudwaleit","year":"2004","unstructured":"Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004;63(6):665\u201370.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"160_CR66","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/ard.2010.139667","volume":"70","author":"IH Song","year":"2011","unstructured":"Song IH, Hermann K, Haibel H, Althoff CE, Listing J, Burmester G, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis. 2011;70(4):590\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"160_CR67","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.3899\/jrheum.140056","volume":"41","author":"IH Song","year":"2014","unstructured":"Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, et al. Consistently good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial. J Rheumatol. 2014;41(10):2034\u201340.","journal-title":"J Rheumatol"},{"issue":"10","key":"160_CR68","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"N Haroon","year":"2013","unstructured":"Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65(10):2645\u201354.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"160_CR69","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/art.21054","volume":"52","author":"A Wanders","year":"2005","unstructured":"Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756\u201365.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"160_CR70","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","volume":"75","author":"J Sieper","year":"2016","unstructured":"Sieper J, Listing J, Poddubnyy D, Song I-H, Hermann K-G, Callhoff J, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis. 2016;75(8):1438\u201343.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"160_CR71","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, et al. American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol (Hoboken, NJ). 2016;68(2):282\u201398.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"1","key":"160_CR72","first-page":"60","volume":"5","author":"JW Boersma","year":"1976","unstructured":"Boersma JW. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scand J Rheumatol. 1976;5(1):60\u20134.","journal-title":"Scand J Rheumatol"},{"issue":"10","key":"160_CR73","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","volume":"71","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 2012;71(10):1616\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"160_CR74","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","volume":"71","author":"F Kroon","year":"2012","unstructured":"Kroon F, Landewe R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71(10):1623\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"160_CR75","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/1756-185X.13270","volume":"21","author":"H Jeong","year":"2018","unstructured":"Jeong H, Eun YH, Kim IY, Park EJ, Kim H, Lee J, et al. Effect of tumor necrosis factor alpha inhibitors on spinal radiographic progression in patients with ankylosing spondylitis. Int J Rheum Dis. 2018;21(5):1098\u2013105.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"160_CR76","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","volume":"77","author":"C Molnar","year":"2018","unstructured":"Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis. 2018;77(1):63\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"160_CR77","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/BOR.0000000000000025","volume":"26","author":"GH Louie","year":"2014","unstructured":"Louie GH, Ward MM. Measurement and treatment of radiographic progression in ankylosing spondylitis: lessons learned from observational studies and clinical trials. Curr Opin Rheumatol. 2014;26(2):145\u201350.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"160_CR78","first-page":"426","volume":"36","author":"H Tannenbaum","year":"1984","unstructured":"Tannenbaum H, DeCoteau WE, Esdaile JM. A double blind multicenter trial comparing piroxicam and indomethacin in ankylosing spondylitis with long-term follow-up. Curr Therapeut Res - Clin Exp. 1984;36(3):426\u201335.","journal-title":"Curr Therapeut Res - Clin Exp"},{"issue":"2","key":"160_CR79","first-page":"70","volume":"9","author":"G Astorga","year":"1987","unstructured":"Astorga G. Double-blind, parallel clinical trial of tenoxicam (Ro 12\u20130068) versus piroxicam in patients with ankylosing spondylitis. Eur J Rheumatol Inflamm. 1987;9(2):70\u20133.","journal-title":"Eur J Rheumatol Inflamm"},{"issue":"3, Supplement 2","key":"160_CR80","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0049-0172(86)80015-4","volume":"15","author":"JR Caldwell","year":"1986","unstructured":"Caldwell JR, Altman RD, Burch FX, Calin A. Treatment of ankylosing spondylitis with oxaprozin: a comparison with indomethacin. Semin Arthritis Rheum. 1986;15(3, Supplement 2):95\u2013100.","journal-title":"Semin Arthritis Rheum"},{"issue":"17","key":"160_CR81","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1001\/jama.1979.03300170031022","volume":"242","author":"A Calin","year":"1979","unstructured":"Calin A, Britton M. Sulindac in ankylosing spondylitis. Double-blind evaluation of sulindac and indomethacin. JAMA. 1979;242(17):1885\u20136.","journal-title":"JAMA."},{"issue":"21","key":"160_CR82","first-page":"597","volume":"80","author":"KK Heinrichs","year":"1985","unstructured":"Heinrichs KK. Treatment of spondylitis ankylosans: controlled comparative study with tiaprofenic acid and diclofenac. Med Klin. 1985;80(21):597\u2013601.","journal-title":"Med Klin"},{"issue":"2 Suppl 1","key":"160_CR83","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/S0049-0172(85)80016-0","volume":"15","author":"MA Khan","year":"1985","unstructured":"Khan MA. Diclofenac in the treatment of ankylosing spondylitis: review of worldwide clinical experience and report of a double-blind comparison with indomethacin. Semin Arthritis Rheum. 1985;15(2 Suppl 1):80\u20134.","journal-title":"Semin Arthritis Rheum"},{"issue":"3A","key":"160_CR84","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0002-9343(86)90129-4","volume":"80","author":"PL Lomen","year":"1986","unstructured":"Lomen PL, Turner LF, Lamborn KR, Brinn EL. Flurbiprofen in the treatment of ankylosing spondylitis. a comparison with indomethacin. Am J Med. 1986;80(3A):127\u201332.","journal-title":"Am J Med"},{"issue":"3A","key":"160_CR85","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/0002-9343(86)90128-2","volume":"80","author":"PL Lomen","year":"1986","unstructured":"Lomen PL, Turner LF, Lamborn KR, Brinn EL, Sattler LP. Flurbiprofen in the treatment of ankylosing spondylitis. A comparison with phenylbutazone. Am J Med. 1986;80(3A):120\u20136.","journal-title":"Am J Med"},{"issue":"7","key":"160_CR86","first-page":"1200","volume":"23","author":"E Batlle-Gualda","year":"1996","unstructured":"Batlle-Gualda E, Figueroa M, Ivorra J, Raber A. The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group. J Rheumatol. 1996;23(7):1200\u20136.","journal-title":"J Rheumatol"},{"issue":"8","key":"160_CR87","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1097\/00007611-197708000-00014","volume":"70","author":"HR Mena","year":"1977","unstructured":"Mena HR, Good AE. Management of ankylosing spondylitis with flurbiprofen or indomethacin. South Med J. 1977;70(8):945\u20137.","journal-title":"South Med J"},{"issue":"21","key":"160_CR88","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3109\/03009747809095674","volume":"7","author":"M Nissila","year":"1978","unstructured":"Nissila M, Kajander A. Proquazone (Biarison) and indomethacin (Indocid) in the treatment of ankylosing spondylitis. Two comparative, clinical, double-blind studies. Scand J Rheumatol Suppl. 1978;7(21):36\u20139.","journal-title":"Scand J Rheumatol Suppl"},{"issue":"2","key":"160_CR89","first-page":"23","volume":"11","author":"TG Palferman","year":"1991","unstructured":"Palferman TG, Webley M. A comparative study of nabumetone and indomethacin in ankylosing spondylitis. Eur J Rheumatol Inflamm. 1991;11(2):23\u20139.","journal-title":"Eur J Rheumatol Inflamm"},{"issue":"7","key":"160_CR90","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/S0011-393X(05)80777-5","volume":"55","author":"G Pasero","year":"1994","unstructured":"Pasero G, Ruju G, Marcolongo R, Senesi M, Seni U, Mannoni A, Mannoni A, et al. Aceclofenac versus naproxen in the treatment of ankylosing spondylitis: A double-blind, controlled study. Curr Therapeut Res - Clin Exp. 1994;55(7):833\u201342.","journal-title":"Curr Therapeut Res - Clin Exp"},{"key":"160_CR91","first-page":"1","volume":"36","author":"V Rejholec","year":"1980","unstructured":"Rejholec V, Vapaatalo H, Tokola O, Gothoni G. Tolfenamic acid in ankylosing spondylarthritis: a double-blind comparison to indomethacin. Scand J Rheumatol Suppl. 1980;36:1\u20137.","journal-title":"Scand J Rheumatol Suppl"},{"issue":"2","key":"160_CR92","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/BF02032359","volume":"5","author":"MJ Franssen","year":"1986","unstructured":"Franssen MJ, Gribnau FW, van de Putte LB. A comparison of diflunisal and phenylbutazone in the treatment of ankylosing spondylitis. Clin Rheumatol. 1986;5(2):210\u201320.","journal-title":"Clin Rheumatol"},{"issue":"Suppl 5","key":"160_CR93","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/rheumatology\/15.5.37","volume":"15","author":"JD Jessop","year":"1976","unstructured":"Jessop JD. Double-blind study of ketoprofen and phenylbutazone in ankylosing spondylitis. Rheumatol Rehabil. 1976;15(Suppl 5):37\u201342.","journal-title":"Rheumatol Rehabil"},{"issue":"10","key":"160_CR94","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1185\/03007999009112691","volume":"11","author":"AC Schwarzer","year":"1990","unstructured":"Schwarzer AC, Cohen M, Arnold MH, Kelly D, McNaught P, Brooks PM. Tenoxicam compared with diclofenac in patients with ankylosing spondylitis. Curr Med Res Opin. 1990;11(10):648\u201353.","journal-title":"Curr Med Res Opin"},{"key":"160_CR95","doi-asserted-by":"crossref","unstructured":"Simpson MR, Simpson NR, Scott BO, Beatty DC. A controlled study of flufenamic acid in ankylosing spondylitis. A preliminary report. Ann Phys Med. 1966;8(Suppl 1):126\u20138.","DOI":"10.1093\/rheumatology\/VIII.suppl_1.126"},{"issue":"17\u201318","key":"160_CR96","first-page":"1485","volume":"106","author":"G Myklebust","year":"1986","unstructured":"Myklebust G. Comparison of naproxen and piroxicam in rheumatoid arthritis and Bechterew's syndrome. A double-blind parallel multicenter study. Tidsskr Nor Laegeforen. 1986;106(17\u201318):1485\u20137.","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"3","key":"160_CR97","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/rheumatology\/19.3.193","volume":"19","author":"AM Nahir","year":"1980","unstructured":"Nahir AM, Scharf Y. A comparative study of diclofenac and sulindac in ankylosing spondylitis. Rheumatol Rehabil. 1980;19(3):193\u20138.","journal-title":"Rheumatol Rehabil"},{"issue":"2","key":"160_CR98","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1177\/030006058801600210","volume":"16","author":"JE Santo","year":"1988","unstructured":"Santo JE, Queiroz MV. Oxaprozin versus diclofenac sodium in the treatment of ankylosing spondylitis. J Int Med Res. 1988;16(2):150\u20136.","journal-title":"J Int Med Res"},{"issue":"Suppl 2","key":"160_CR99","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/030006057700502S19","volume":"5","author":"BM Ansell","year":"1977","unstructured":"Ansell BM. A comparative study of Butacote and naproxen in ankylosing spondylitis. J Int Med Res. 1977;5(Suppl 2):95.","journal-title":"J Int Med Res"},{"issue":"9894","key":"160_CR100","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"N Bhala","year":"2013","unstructured":"Coxib, traditional NTC, Bhala N, Emberson J, Merhi A, Abramson S, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769\u201379.","journal-title":"Lancet"},{"issue":"7553","key":"160_CR101","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","volume":"332","author":"PM Kearney","year":"2006","unstructured":"Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Bmj. 2006;332(7553):1302\u20138.","journal-title":"Bmj."},{"issue":"4","key":"160_CR102","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1136\/annrheumdis-2013-204155","volume":"74","author":"A Lanas","year":"2015","unstructured":"Lanas A, Boers M, Nuevo J. Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice. Ann Rheum Dis. 2015;74(4):675\u201381.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"160_CR103","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.rdc.2012.08.005","volume":"38","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy D, van der Heijde D. Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs. Rheum Dis Clin North Am. 2012;38(3):601\u201311.","journal-title":"Rheum Dis Clin North Am"},{"issue":"11","key":"160_CR104","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1136\/ard.2011.151191","volume":"70","author":"G Bakland","year":"2011","unstructured":"Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011;70(11):1921\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"160_CR105","doi-asserted-by":"publisher","first-page":"409","DOI":"10.7326\/M14-2470","volume":"163","author":"NN Haroon","year":"2015","unstructured":"Haroon NN, Paterson JM, Li P, Inman RD, Haroon N. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med. 2015;163(6):409\u201316.","journal-title":"Ann Intern Med"},{"issue":"3","key":"160_CR106","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1136\/ard.52.3.174","volume":"52","author":"K Lehtinen","year":"1993","unstructured":"Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis. 1993;52(3):174\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"160_CR107","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.berh.2019.01.002","volume":"32","author":"JW Liew","year":"2018","unstructured":"Liew JW, Ramiro S, Gensler LS. Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018;32(3):369\u201389.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"160_CR108","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/clpt.2008.204","volume":"85","author":"EL Fosbol","year":"2009","unstructured":"Fosbol EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009;85(2):190\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"160_CR109","doi-asserted-by":"publisher","first-page":"c7086","DOI":"10.1136\/bmj.c7086","volume":"342","author":"S Trelle","year":"2011","unstructured":"Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. Bmj. 2011;342:c7086.","journal-title":"Bmj."},{"issue":"25","key":"160_CR110","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1161\/CIRCULATIONAHA.106.616219","volume":"113","author":"GH Gislason","year":"2006","unstructured":"Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113(25):2906\u201313.","journal-title":"Circulation."},{"issue":"11","key":"160_CR111","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJMoa050330","volume":"352","author":"NA Nussmeier","year":"2005","unstructured":"Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352(11):1081\u201391.","journal-title":"N Engl J Med"},{"issue":"8","key":"160_CR112","first-page":"1137","volume":"77","author":"M Dubreuil","year":"2018","unstructured":"Dubreuil M, Louie-Gao Q, Peloquin CE, Choi HK, Zhang Y, Neogi T. Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis. Ann Rheum Dis. 2018;77(8):1137\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"160_CR113","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.amjmed.2008.06.035","volume":"121","author":"WC Winkelmayer","year":"2008","unstructured":"Winkelmayer WC, Waikar SS, Mogun H, Solomon DH. Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am J Med. 2008;121(12):1092\u20138.","journal-title":"Am J Med"},{"issue":"4","key":"160_CR114","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejim.2015.03.008","volume":"26","author":"P Ungprasert","year":"2015","unstructured":"Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015;26(4):285\u201391.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"160_CR115","doi-asserted-by":"publisher","first-page":"280 e1","DOI":"10.1016\/j.amjmed.2006.02.015","volume":"120","author":"K Gooch","year":"2007","unstructured":"Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, et al. NSAID use and progression of chronic kidney disease. Am J Med. 2007;120(3):280 e1\u20137.","journal-title":"Am J Med"},{"issue":"38","key":"160_CR116","doi-asserted-by":"publisher","first-page":"13956","DOI":"10.3748\/wjg.v20.i38.13956","volume":"20","author":"YL Cao","year":"2014","unstructured":"Cao YL, Tian ZG, Wang F, Li WG, Cheng DY, Yang YF, et al. Characteristics and clinical outcome of nonsteroidal anti-inflammatory drug-induced acute hepato-nephrotoxicity among Chinese patients. World J Gastroenterol. 2014;20(38):13956\u201365.","journal-title":"World J Gastroenterol"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-020-00160-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s42358-020-00160-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-020-00160-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:43:56Z","timestamp":1697589836000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-020-00160-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["160"],"URL":"https:\/\/doi.org\/10.1186\/s42358-020-00160-6","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]},"assertion":[{"value":"3 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ricardo da Cruz Lage received lecture fees from Abbvie, Pfizer and Novartis; sponsorship for events from Janssen, Novartis, Pfizer and Abbvie; research payments from Abbvie.Cl\u00e1udia Diniz Lopes Marques received lecture fees from Abbvie, Janssen, Pfizer and Novartis; advisory board from Novartis and Abbvie; sponsorship for events from Abbvie, Janssen, Pfizer, Novartis, and Lilly.Thauana Lu\u00edza Oliveira received lecturer fees from Abbvie, Novartis and Janssen; support to congresses from Abbvie and Janssen.Gustavo Gomes Resende received lecture fees from Abbvie, Janssen, Novartis, Pfizer, and UCB; advisory board from Abbvie, Janssen, and Novartis; Research support from Brazilian Society of Rheumatology, FAPEMIG and UCB; clinical research payments from Abbvie and Pfizer; sponsorship for scientific events from Abbvie, Janssen, Lilly, Novartis, Pfizer, and UCB.Charles Lubianca Kohen received financial support for advisory board participation from Novartis; speaker fee from Janssen, Abbvie, Novartis, Pfizer, UCB; support to events from Janssen, Abbvie, Roche, Astra-Zeneca, Novartis.Carla Gon\u00e7alves Saad has no conflicts of interest.Ant\u00f4nio Carlos Ximenes received payments for participation in clinical research from Abbvvie, Pfizer, Roche, BMS, and Amgen; on scientific board of Pfizer, and Abbivie; as a lecturer from AbbVie, Pfizer, and Abbott.C\u00e9lio Roberto Gon\u00e7alves has no conflicts of interest.Washington Alves Bianchi has no conflicts of interest.Eduardo de Souza Meirelles received payments as a speaker from Novartis, Abbvie, Abbott and Marjan; research grants from Novartis and Pfizer; support for conferences and courses from Ach\u00e9, Pfizer, Novartis, Janssen, Abbvie, Roche, and Lilly; Advisory board fee from Novartis and Marjan.Mauro Waldemar Keiserman received financial support for lectures, advisory bord and clinical research from Abbvie, Actelion, Biogen, Bristol, Celltrion, Lilly, Human Genome Sceiences, Janssen, Pfizer, Novartis, Roche, Sanofi, and UCB.Adriano Chiereghin received honoraria as a speaker from Janssen, Novartis, UCB, and Pfizer; support to courses and congresses from Abbvie, Janssen, Novartis, UCB, and Pfizer; advisory board from Novartis and Janssen.Cristiano Barbosa Campanholo received financial support for advisory board participation from Janssen, Abbvie, Bristol, Lilly, Novartis, Pfizer, UCB; speaker fee from Janssen, Abbvie, Lilly, Novartis, and Pfizer, UCB; support to events from Janssen, Abbvie, Bristol, Novartis, and Pfizer.Andre Marun Lyrio received payments from Speaker of Janssen and UCB; support to courses\/congresses from Janssen, Abbvie, Pfizer, UBC, Novartis, and Lily.Cl\u00e1udia Goldenstein Schainberg has participated in the pharmaceutical advisory board of AbbVie, Janssen, Lilly, Novartis, and Pfizer; is a speaker invited by AbbVie, Janssen, Lilly, Novartis, Pfizer; has no stock of these pharmaceutical industries.Lenise Brandao Pieruccetti has no conflicts of interest.Michel Alexandre Yazbek received financial support from Abbvie, UCB, Novartis and Lilly.Penelope Esther Palominos has no conflicts of interest.Rafaela Silva Guimar\u00e3es Goncalves received fees for lectures from Janssen, Novertis, Abbvie, Apsen, Bristol, and Pfizer; advisory board from Janssen.Rodrigo Luppino Assad received fees for lectures and advisory board from Abbvie, Novartis, Janssen, UCB, Lilly, and Bristol; research support from Abbvie and UCB.Rubens Bonfiglioli received financial support for clinical research from Roche, Pfizer, Amgen, and Novartis; for scientific advisory from Lilly, Abbvie, Roche, and UCB; for support to events from Roche, Pfizer, Abbvie and Novartis; for symposia and sponsored meetings from Roche, Pfizer, and Janssen.S\u00f4nia Maria Alvarenga Anti received financial support from Abbvie, Jansen, Novartis, Lilly, and UCB.Sueli Coelho da Silva Carneiro received honorary speaker from Abbvie, Janssen, Lilly, Novartis and Pfizer; support to research from CNPq and FAPERJ; support for congresses from Abbvie, Janssen, Novartis, Pfizer, CNPq and FAPERJ; advisory board from Janssen, Lilly, and Novartis.Valder\u00edlio Feij\u00f3 Azevedo is GRAPPA member; Medical diretor of Edumed Biotech; received for clinical research from Pfizer, Roche, Janssen, Bristol, Abbvie, Medimmune, Boehringer, GSK, USB, Sanofi, Takeda, Bird Rock Bio, and NovoNordisk; financial support to events and lectures from Pfizer, Hospira, Roche, MSD, BMS, Merck Senoro, Janssen, Novertis, Celltrion, UCB, and AztraZeneca.Cleandro Pires Albuquerque has no conflicts of interest.Wanderley Marques Bernardo has no conflicts of interest.Percival Degrava Sampaio-Barros received for participation in lectures, boards or scientific events from laboratories Abbvie, Janssen, Novartis, Pfizer and UCB.Marcelo de Medeiros Pinheiro received financial support for advisory board from Novartis and Janssen; by lectures from Novartis, Janssen, Abbvie.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}